Bristol Myers Squibb Stock Fundamentals
| BMY Stock | USD 58.87 0.64 1.10% |
Bristol Myers Squibb fundamentals help investors to digest information that contributes to Bristol Myers' financial success or failures. It also enables traders to predict the movement of Bristol Stock. The fundamental analysis module provides a way to measure Bristol Myers' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Bristol Myers stock.
At this time, Bristol Myers' Net Income Applicable To Common Shares is fairly stable compared to the past year. Net Income From Continuing Ops is likely to rise to about 8.7 B in 2024, whereas Selling General Administrative is likely to drop slightly above 3.6 B in 2024. Bristol | Select Account or Indicator |
Bristol Myers Squibb Company Operating Margin Analysis
Bristol Myers' Operating Margin shows how much operating income a company makes on each dollar of sales. It is one of the profitability indicators which helps analysts to understand whether the firm is successful or not making money from everyday operations.
Current Bristol Myers Operating Margin | 0.18 % |
Most of Bristol Myers' fundamental indicators, such as Operating Margin, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Bristol Myers Squibb is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Bristol Operating Margin Historical Pattern
Today, most investors in Bristol Myers Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Bristol Myers' growth ratios. Consistent increases or drops in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's operating margin growth rates may not be enough to decide which company is a better investment. That's why investors frequently use a static breakdown of Bristol Myers operating margin as a starting point in their analysis.
Bristol Myers Operating Margin |
| Timeline |
A good Operating Margin is required for a company to be able to pay for its fixed costs or payout its debt, which implies that the higher the margin, the better. This ratio is most effective in evaluating the earning potential of a company over time when comparing it against a firm's competitors.
| Competition |
Bristol Pretax Profit Margin
Pretax Profit Margin |
|
Based on the recorded statements, Bristol Myers Squibb has an Operating Margin of 0.1848%. This is 100.53% lower than that of the Pharmaceuticals sector and significantly higher than that of the Health Care industry. The operating margin for all United States stocks is 103.35% lower than that of the firm.
Bristol Myers Squibb Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Bristol Myers's current stock value. Our valuation model uses many indicators to compare Bristol Myers value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Bristol Myers competition to find correlations between indicators driving Bristol Myers's intrinsic value. More Info.Bristol Myers Squibb is number one stock in return on equity category among its peers. It also is number one stock in return on asset category among its peers . At this time, Bristol Myers' Return On Equity is fairly stable compared to the past year. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Bristol Myers' earnings, one of the primary drivers of an investment's value.Bristol Myers' Earnings Breakdown by Geography
Bristol Operating Margin Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Bristol Myers' direct or indirect competition against its Operating Margin to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Bristol Myers could also be used in its relative valuation, which is a method of valuing Bristol Myers by comparing valuation metrics of similar companies.Bristol Myers is currently under evaluation in operating margin category among its peers.
Bristol Myers ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Bristol Myers' sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Bristol Myers' managers, analysts, and investors.Environmental | Governance | Social |
Bristol Fundamentals
| Return On Equity | -0.31 | ||||
| Return On Asset | 0.0607 | ||||
| Profit Margin | (0.15) % | ||||
| Operating Margin | 0.18 % | ||||
| Current Valuation | 162.7 B | ||||
| Shares Outstanding | 2.03 B | ||||
| Shares Owned By Insiders | 0.11 % | ||||
| Shares Owned By Institutions | 78.41 % | ||||
| Number Of Shares Shorted | 23.42 M | ||||
| Price To Earning | 24.88 X | ||||
| Price To Book | 6.97 X | ||||
| Price To Sales | 2.52 X | ||||
| Revenue | 45.01 B | ||||
| Gross Profit | 36.38 B | ||||
| EBITDA | 19.42 B | ||||
| Net Income | 8.04 B | ||||
| Cash And Equivalents | 9.12 B | ||||
| Cash Per Share | 6.21 X | ||||
| Total Debt | 41.46 B | ||||
| Debt To Equity | 1.32 % | ||||
| Current Ratio | 1.42 X | ||||
| Book Value Per Share | 8.45 X | ||||
| Cash Flow From Operations | 13.86 B | ||||
| Short Ratio | 2.30 X | ||||
| Earnings Per Share | (3.58) X | ||||
| Price To Earnings To Growth | 2.06 X | ||||
| Target Price | 59.37 | ||||
| Number Of Employees | 34.1 K | ||||
| Beta | 0.44 | ||||
| Market Capitalization | 119.4 B | ||||
| Total Asset | 95.16 B | ||||
| Retained Earnings | 28.77 B | ||||
| Working Capital | 9.51 B | ||||
| Current Asset | 10.41 B | ||||
| Current Liabilities | 8.02 B | ||||
| Annual Yield | 0.04 % | ||||
| Five Year Return | 2.96 % | ||||
| Net Asset | 95.16 B | ||||
| Last Dividend Paid | 2.4 |
About Bristol Myers Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Bristol Myers Squibb's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Bristol Myers using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Bristol Myers Squibb based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.| Last Reported | Projected for Next Year | ||
| Current Deferred Revenue | 8.4 B | 8.8 B | |
| Total Revenue | 45 B | 47.3 B | |
| Cost Of Revenue | 10.7 B | 5.8 B | |
| Stock Based Compensation To Revenue | 0.01 | 0.01 | |
| Sales General And Administrative To Revenue | 0.16 | 0.18 | |
| Research And Ddevelopement To Revenue | 0.21 | 0.14 | |
| Capex To Revenue | 0.03 | 0.04 | |
| Revenue Per Share | 21.75 | 22.84 | |
| Ebit Per Revenue | 0.37 | 0.25 |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Bristol Stock Analysis
When running Bristol Myers' price analysis, check to measure Bristol Myers' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Bristol Myers is operating at the current time. Most of Bristol Myers' value examination focuses on studying past and present price action to predict the probability of Bristol Myers' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Bristol Myers' price. Additionally, you may evaluate how the addition of Bristol Myers to your portfolios can decrease your overall portfolio volatility.